Midcareer Investigator Award

职业生涯中期研究员奖

• 批准号: 8717403
• 负责人: MATTHEW RAYMOND SMITH
• 金额: $ 18.6万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-06-05 至 2017-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8717403
• 关键词: Acetates; Adverse effects; Anabolism; Androgen Receptor; Androgens; Area; Award; Biological Markers; Body Composition; Bone Density; Cancer Center; Cancer Survivorship; Cessation of life; Clinical; Clinical Investigator; Clinical Research; Commit; Development; Dose; Funding; General Hospitals; Goals; Heterogeneity; Lead; Malignant Neoplasms; Malignant neoplasm of prostate; Massachusetts; Medical Oncologist; Mentors; Metabolic; Metabolism; Metastatic Neoplasm to the Bone; Metastatic Prostate Cancer; Methodology; Microfluidics; Molecular; Neoplasm Circulating Cells; New Agents; Peer Review; Peer Review Grants; Pharmaceutical Preparations; Prevention; Productivity; Receptor Signaling; Research; Research Activity; Research Personnel; Signal Pathway; Time; Training; Vascular Endothelial Growth Factor Receptor; abiraterone; castration resistant prostate cancer; catalyst; clinical care; deprivation; design; drug mechanism; effective therapy; improved; inhibitor/antagonist; male health; men; next generation; novel; patient oriented research; prevent; programs; resistance mechanism; response; small molecule; survivorship; therapy development

DESCRIPTION (provided by applicant): The broad long-term objectives of this K24 renewal are to enhance the research productivity of the candidate and to increase the pool of well-trained clinical researchers who can conduct patient-oriented research, compete for peer reviewed grants, and mentor the next generation of clinical investigators. The Specific Aims are to: (1) develop and expand the candidate's capabilities in patient-oriented research, and (2) mentor new investigators in patient-oriented research. The candidate is a medical oncologist with particular expertise in prostate cancer. He has a strong record of patient-oriented research, independent peer-reviewed funding, and effective mentoring. The candidate's clinical research program focuses on prostate cancer survivorship and the prevention and treatment of bone metastases. In the first 5 years of this K24, the candidate has helped improve the clinical care for men with prostate cancer by identifying previously unrecognized harms of androgen deprivation therapy and by developing effective new treatments for prostate cancer. In the first five years of this K24, the candidate has also successfully mentored 10 junior investigators in patient-oriented research. This K24 renewal coincides with important new directions in the candidate's research program. The research program has been developed and expanded around three research themes: survivorship, biomarkers, and novel therapy. This K24 renewal also coincides with the identification of three new mentees and planned expansion of mentoring responsibilities at Massachusetts General Hospital, Dana Farber Harvard Cancer Center, and the Harvard Catalyst. The support of this K24 renewal is essential to provide the candidate with the protected time necessary to develop and expand patient-oriented research and mentoring.

描述（由申请人提供）：此次 K24 更新的广泛长期目标是提高候选者的研究生产力，并增加训练有素的临床研究人员的数量，这些研究人员可以进行以患者为导向的研究，竞争同行评审的资助，并指导下一代临床研究人员。具体目标是：(1) 发展和扩展候选人在以患者为导向的研究中的能力，以及 (2) 指导新的研究人员以患者为导向的研究。 该候选人是一位在前列腺癌方面具有特殊专业知识的肿瘤内科医生。他在以患者为中心的研究、独立的同行评审资金和有效的指导方面拥有良好的记录。该候选人的临床研究项目重点关注前列腺癌的生存以及骨转移的预防和治疗。在 K24 的前 5 年中，候选人通过识别以前未认识到的雄激素剥夺疗法的危害以及开发有效的前列腺癌新疗法，帮助改善了前列腺癌男性的临床护理。在 K24 的前五年中，候选人还成功指导了 10 名初级研究人员进行以患者为导向的研究。 此次 K24 更新与候选人研究计划中的重要新方向相一致。该研究计划围绕三个研究主题进行开发和扩展：生存、生物标志物和新颖疗法。此次 K24 更新也恰逢马萨诸塞州总医院、达纳法伯哈佛癌症中心和哈佛催化剂中心确定三名新学员，并计划扩大指导职责。 K24 更新的支持对于为候选人提供必要的受保护时间来发展和扩大以患者为导向的研究和指导至关重要。